David Eichenbaum

Nov 5, 2024 | healio.com | David Eichenbaum |Anthony DeFino |Christine Klimanskis

Read more You've successfully added Retina/Vitreous in Ophthalmology to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. In this Healio Video Perspective from the Retina Society meeting, David A.

Oct 24, 2024 | healio.com | David Eichenbaum |Anthony DeFino |Christine Klimanskis

You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. CHICAGO — In this Healio Video Perspective from the AAO meeting, David A. Eichenbaum, MD, discusses results from a phase 1 trial investigating axitinib for the treatment of neovascular age-related macular degeneration.

Oct 3, 2024 | healio.com | David Eichenbaum |Anthony DeFino |Christine Klimanskis

You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. In this Healio Video Perspective from the Retina Society meeting, David A. Eichenbaum, MD, ofRetina Vitreous Associates of Florida, presents promising 12-month results from the DAVIO 2 trial.

Oct 1, 2024 | retinalphysician.com | David Eichenbaum

David A. Eichenbaum, MD, FASRS is director of research at Retina Vitreous Associates of Florida and collaborative associate professor at Morsani College of Medicine, University of South Florida, in Tampa, Florida. He has been a clinical trial investigator for the past 16 years, participating in more than 90 trials studying common retinal diseases such as dry and wet age-related macular degeneration, diabetic eye disease, and retinal vascular disease.

Jun 11, 2024 | healio.com | David Eichenbaum |Eamon Dreisbach |David Mullin |Christine Klimanskis

You've successfully added Retina/Vitreous in Ophthalmology to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. PARK CITY, Utah — In this Healio Video Perspective from Clinical Trials at the Summit, David A. Eichenbaum, MD, presents real-world data related to the use of aflibercept 8 mg.